Pulmonary Embolism Drugs Market Share

North American Market Forecast

The North American pulmonary embolism drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the rising healthcare expenditure backed by the escalating government spending to develop healthcare services. According to a report by the World Health Organization (WHO), as of 2018, the per capita healthcare expenditure of North America is valued at USD 10,050.279. Moreover, the presence of major pharmaceutical companies in the region is estimated to boost market growth during the forecast period.

APAC Market Statistics

The Asia Pacific pulmonary embolism drugs market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. The growth of the market can be attributed majorly to the high prevalence of cancer in the region backed by the growing government initiatives to launch and support programs to provide medical services for people living with cancer. For instance, in 2020, approximately 150 thousand people were estimated to be living with cancer in the Asia Pacific along with the high geriatric population, both of which are major causes of pulmonary embolism.

Europe Market Forecast

The Europe pulmonary embolism drugs market, amongst the market in all the other regions, is projected to hold a notable share during the forecast period. Factors such as, a higher prevalence of cancer in the region and higher demand for healthcare solution backed by the increasing geriatric population is estimated to propel the growth of the market over the forecast period. Moreover, the surge in research & development of pulmonary embolism drugs in the region is also anticipated to drive market growth over the forecast period.